The Russian Health Ministry has registered the nasal version of its Covid-19 vaccine- Sputnik V. It is the world’s first nasal vaccine against coronavirus. The Russian News agency TASS reported in January that nasal vaccine against the deadly COVID-19 infection will be in civil circulation and available for Russians within 3-4 months, quoting the director of the Gamaleya Centre, Alexander Gintsburg. A research institute called the Gamalaya Centre is the manufacturer of Sputnik V.
In October 2021, the Russian health ministry has given approval for the second phase of clinical trials of the coronavirus vaccine in the nasal spray form.
BREAKING: Russian Health Ministry registers the nasal version of Sputnik V, the world’s first nasal vaccine against COVID-19 pic.twitter.com/3rlZhD5yOV
— Sputnik V (@sputnikvaccine) April 1, 2022
“Laboratory tests show the Sputnik V protects against Omicron in its ordinary injection form, and it will certainly be efficient in the nasal form,” Gintsburg told TASS.
The Sputnik V coronavirus vaccine was administered first in India in Hyderabad in May 2021. The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory on May 13, 2021.
Last month, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced that the Ministry of Health of the Republic of Kazakhstan has authorized the use of Sputnik M Russian vaccine for adolescents aged 12-17.
Thus Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.
In contrast with some international producers offering their vaccines in the same dosage for both adults and adolescents, the Gamaleya Center has developed Sputnik M specifically for adolescents.
